This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Oct;11(10):545.

doi: 10.1038/nrurol.2014.227. Epub 2014 Aug 26.

Prostate cancer: Enzalutamide AFFIRMs its benefits

Robert Phillips

PMID: 25155796
DOI: 10.1038/nrurol.2014.227

Comment

Prostate cancer: Enzalutamide AFFIRMs its benefits

Robert Phillips. Nat Rev Urol. 2014 Oct.

. 2014 Oct;11(10):545.

doi: 10.1038/nrurol.2014.227. Epub 2014 Aug 26.

Author

Robert Phillips

PMID: 25155796
DOI: 10.1038/nrurol.2014.227

No abstract available

PubMed Disclaimer

Comment on

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.
Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, Forer D, Hirmand M, de Bono JS. Fizazi K, et al. Lancet Oncol. 2014 Sep;15(10):1147-56. doi: 10.1016/S1470-2045(14)70303-1. Epub 2014 Aug 4. Lancet Oncol. 2014. PMID: 25104109 Clinical Trial.

References

1. Lancet Oncol. 2014 Sep;15(10):1147-56 - PubMed
1. Eur Urol. 2015 Aug;68(2):317-24 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.